In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry
Portfolio Pulse from Benzinga Insights
The analysis compares Eli Lilly (LLY) against its competitors in the Pharmaceuticals industry, focusing on financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Eli Lilly shows a premium valuation with high P/E, P/B, and P/S ratios, a strong ROE, and significant revenue growth, but its EBITDA and gross profit are below the industry average. The company's higher debt-to-equity ratio indicates increased financial risk.
March 08, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Eli Lilly shows a premium valuation with high P/E, P/B, and P/S ratios, a strong ROE, and significant revenue growth, but its EBITDA and gross profit are below the industry average. The company's higher debt-to-equity ratio indicates increased financial risk.
Eli Lilly's high valuation ratios (P/E, P/B, P/S) and strong ROE indicate investor confidence and potential for growth, which could maintain or slightly increase its stock price. However, the below-average EBITDA and gross profit, coupled with a high debt-to-equity ratio, may raise concerns about operational efficiency and financial risk, potentially offsetting some of the positive sentiment.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100